(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau





(43) International Publication Date 31 July 2003 (31.07.2003)

PCT

(10) International Publication Number WO 03/062276 A2

(51) International Patent Classification7:

C07K 14/52

(21) International Application Number: PCT/GB03/00253

(22) International Filing Date: 24 January 2003 (24.01.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 0201679.8

25 January (2002 (25.01.2002) GB

(71) Applicant (for all designated States except US): ASTE-RION LIMITED [GB/GB]; Firth Court, Western Bank, Sheffield S10 2TN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): ROSS, Richard


[GB/GB]; Chemical Sciences, Northern General Hospital, Sheffield S5 7ALL (GB). ARTYMIUK, Peter [GB/GB]; University of Sheffield, Dept. of Molecular Biology and Biotechnology, Sheffield S10 2TN (GB). SAYERS, Jon [GB/GB]; University of Sheffield, Division of Genomic Medicine Infection & Immunity, Medical School, F Floor, Beech Hill Road, Sheffield S10 2RX (GB).

(74) Agent: HARRISON, GODDARD, FOOTE; Belgrave Hall, Belgrave Street, Leeds LS2 8DD (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

[Continued on next page]

(54) Title: POLYPEPTIDE VARIANTS



(57) Abstract: The invention relates to the provision of oligomeric polypeptides (dimers, trimers, etc) comprising the ligand binding domains of cytokines which are linked via flexible polypeptide linker The linker molecules molecules. optionally protease comprise sensitive sites to modulate the release of biologically active cytokines when administered to a human or animal subject.

WO 03/062276 A2

BEST AVAILABLE COPY